Breaking News
Get 50% Off 0
NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔 Read more
Close

Nippon India Pharma Fund - Direct Plan - Bonus Plan (0P0000XVFI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
492.143 +3.750    +0.77%
28/06 - Closed. Currency in INR ( Disclaimer )
  • Morningstar Rating:
  • Total Assets: 71.61B
Type:  Fund
Market:  India
Issuer:  Reliance Nippon Life Asset Management Ltd
ISIN:  INF204K01I27 
Asset Class:  Equity
Reliance Pharma Fund - Direct Plan - Bonus Plan 492.143 +3.750 +0.77%

0P0000XVFI Holdings

 
Comprehensive information about top holdings and Key Holding Information for the Reliance Pharma Fund - Direct Plan - Bonus Plan (0P0000XVFI) fund. Our Reliance Pharma Fund - Direct Plan - Bonus Plan portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 1.620 1.800 0.180
Stocks 98.380 98.380 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 34.145 33.521
Price to Book 5.166 4.784
Price to Sales 4.646 4.665
Price to Cash Flow 23.438 24.218
Dividend Yield 0.869 0.739
5 Years Earnings Growth 18.419 17.530

Sector Allocation

Name  Net % Category Average
Healthcare 100.000 97.144

Region Allocation

  • Asia
  • Emerging Markets

Top Holdings

Number of long holdings: 33

Number of short holdings: 1

Name ISIN Weight % Last Change %
  Sun Pharma INE044A01036 13.37 1,519.80 +0.23%
  Lupin INE326A01037 7.74 1,626.00 +2.69%
  Divi's Labs INE361B01024 7.52 4,590.90 +1.52%
  Cipla INE059A01026 6.26 1,482.00 +0.07%
  Apollo Hospitals INE437A01024 5.29 6,190.00 -0.04%
  Dr Reddy’s Laboratories INE089A01023 4.45 6,400.00 +2.63%
  Gland INE068V01023 4.37 1,825.30 +0.44%
  Zydus Lifesciences INE010B01027 3.77 1,078.60 +2.04%
  Vijaya Diagnostic Centre INE043W01024 3.59 747.50 -0.79%
  J.B. Chemicals&Pharma INE572A01036 3.16 1,754.05 +4.30%

Top Equity Funds by Nippon Life India Asset Management Ltd

  Name Rating Total Assets YTD% 3Y% 10Y%
  Reliance Small Cap Fund Growth 515.66B 12.81 32.36 25.25
  Reliance Small Cap Fund Dir Bon 515.66B 13.19 33.51 26.46
  Reliance Small Cap Fund Dir Gr 515.66B 12.57 34.64 26.79
  Reliance Small Cap Fund Dir Div 515.66B 13.19 33.51 26.46
  Reliance Small Cap Fund Bonus 515.66B 12.81 32.36 25.25
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0000XVFI Comments

Write your thoughts about Nippon India Pharma Fund - Direct Plan - Bonus Plan
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email